Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M SESTAMIBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M SESTAMIBI.
NEPHROSCAN vs TECHNETIUM TC 99M SESTAMIBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Technetium Tc 99m sestamibi is a cationic lipophilic complex that passively diffuses across cell membranes and accumulates in mitochondria due to the negative mitochondrial membrane potential. It is used as a myocardial perfusion imaging agent to visualize blood flow to the heart muscle.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
Myocardial imaging: 740-1110 MBq (20-30 mCi) IV bolus, single dose. Parathyroid imaging: 740-925 MBq (20-25 mCi) IV bolus, single dose.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: approximately 6 hours (range 4–8 hours) for myocardial clearance. Delayed clearance may occur in patients with hepatic or renal impairment.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Primarily renal: approximately 33% of injected dose excreted in urine within 8 hours, increasing to about 50% by 24 hours. Hepatic uptake with subsequent biliary excretion accounts for the remainder; fecal elimination is less than 2% of administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical